BR0114898A - Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp - Google Patents

Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp

Info

Publication number
BR0114898A
BR0114898A BR0114898-2A BR0114898A BR0114898A BR 0114898 A BR0114898 A BR 0114898A BR 0114898 A BR0114898 A BR 0114898A BR 0114898 A BR0114898 A BR 0114898A
Authority
BR
Brazil
Prior art keywords
addiction
pcp
modifying
behavior
improving
Prior art date
Application number
BR0114898-2A
Other languages
English (en)
Inventor
Stephen L Dewey
Jonathan D Brodie
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of BR0114898A publication Critical patent/BR0114898A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODOS PARA MODIFICAR O COMPORTAMENTO RELACIONADO COM ADICçãO DE UM MAMìFERO SOFRENDO DE ADICçãO DE PCP, E DE MELHORIA DOS EFEITOS DA ADICçãO DE PCP". A presente invenção proporciona um método para modificar o comportamento relacionado com adicção de um mamífero sofrendo de adicção de drogas alucinógenas, preferivelmente fenilciclidina (PCP). O método inclui a administração ao mamífero de uma quantidade efetiva de gama-vinilGABA (GVG) ou de um seu sal farmaceuticamente aceitável, ou de um seu enanciómero, ou de uma sua mistura racêmica, sendo que a quantidade efetiva é suficiente para diminuir, inibir ou eliminar o comportamento associado com desejo incontrolável ou uso de PCP.
BR0114898-2A 2000-10-23 2001-03-07 Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp BR0114898A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/694,040 US6395783B1 (en) 2000-10-23 2000-10-23 Treatment of PCP addiction and PCP addiction-related behavior
PCT/US2001/007233 WO2002034249A1 (en) 2000-10-23 2001-03-07 Treatment of pcp addiction and pcp addiction-related behavior

Publications (1)

Publication Number Publication Date
BR0114898A true BR0114898A (pt) 2003-08-12

Family

ID=24787164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114898-2A BR0114898A (pt) 2000-10-23 2001-03-07 Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp

Country Status (17)

Country Link
US (1) US6395783B1 (pt)
EP (1) EP1335717A4 (pt)
JP (1) JP2004512301A (pt)
KR (1) KR20030074610A (pt)
CN (2) CN1771929A (pt)
AU (2) AU4201101A (pt)
BR (1) BR0114898A (pt)
CA (1) CA2426210C (pt)
CZ (1) CZ20031431A3 (pt)
HR (1) HRP20030322A2 (pt)
HU (1) HUP0301441A3 (pt)
IL (2) IL155574A0 (pt)
MX (1) MXPA03003589A (pt)
NO (1) NO20031814L (pt)
NZ (1) NZ526072A (pt)
PL (1) PL361028A1 (pt)
WO (1) WO2002034249A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN114903006B (zh) * 2021-02-09 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物物质成瘾模型的构建方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
DE3882712D1 (de) 1987-10-07 1993-09-02 Matrix Technologies Inc Pharmazeutische zusammensetzung fuer die behandlung der kokainsucht.
US5102913A (en) * 1991-07-01 1992-04-07 Halikas James A Treatment for cocaine use employing valproic acid
HUP0100115A2 (hu) 1997-10-28 2001-06-28 Schering Corp. Eljárás kóros vágy csökkentésére emlősökben
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.

Also Published As

Publication number Publication date
HUP0301441A3 (en) 2011-07-28
EP1335717A4 (en) 2004-06-30
CN1771929A (zh) 2006-05-17
CN1234352C (zh) 2006-01-04
KR20030074610A (ko) 2003-09-19
HRP20030322A2 (en) 2005-02-28
AU2001242011B2 (en) 2005-11-03
MXPA03003589A (es) 2005-08-16
JP2004512301A (ja) 2004-04-22
CZ20031431A3 (cs) 2004-06-16
CA2426210C (en) 2009-12-22
HUP0301441A2 (hu) 2003-11-28
NO20031814L (no) 2003-06-19
NO20031814D0 (no) 2003-04-23
CN1476326A (zh) 2004-02-18
IL155574A (en) 2010-02-17
NZ526072A (en) 2004-08-27
US6395783B1 (en) 2002-05-28
EP1335717A1 (en) 2003-08-20
AU2001242011B8 (en) 2006-03-02
CA2426210A1 (en) 2002-05-02
IL155574A0 (en) 2003-11-23
AU4201101A (en) 2002-05-06
PL361028A1 (en) 2004-09-20
WO2002034249A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
BR9912760A (pt) Usos de gama vinilgaba (gvg) e de uma composição que aumenta os nìveis de gaba do sistema nervoso central
Powell et al. Comparative effects of cyclo‐oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance
Hwang et al. Analgesic properties of intrathecally administered heterocyclic antidepressants
KR930007450A (ko) 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물
BR9714739A (pt) Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu
NO20070578L (no) Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol
BR0211317A (pt) Sistema para a liberação controlada de uma droga por meio de retenção gástrica
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
KR930003912A (ko) 울혈성 심장 마비 치료법
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BR9809492A (pt) Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma
DK0904067T3 (da) Transdermalt indgivet dextromethorpan som hostestillende middel
Maurice et al. The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (σ) receptor ligands involves both σ1 and σ2 sites
BRPI0015939B8 (pt) sistema terapêutico transdérmico com estabilidade aperfeiçoada e processo para a sua preparação
NZ506408A (en) Pharmaceutical compositions
BR0114898A (pt) Métodos para modificar o comportamento relacionado com adicção de um mamìfero sofrendo de adicção de pcp, e de melhoria dos efeitos da adicção de pcp
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.